Form 4: Vertex Pharmaceuticals Executive Chairman Reports Stock Disposal to Cover Tax Obligations
SEC Form 4 Filing
Jeffrey M. Leiden, Executive Chairman of Vertex Pharmaceuticals, disposed of shares to cover tax obligations arising from vested restricted stock units.
Summary
- On February 14, 2025, Jeffrey M. Leiden, the Executive Chairman of Vertex Pharmaceuticals, disposed of 6,066 shares of common stock to cover tax obligations.
- The transaction was executed at a price of $463.46 per share.
- Following the transaction, Leiden directly owns 24,026 shares of Vertex Pharmaceuticals common stock.
- Leiden also indirectly owns 440 shares through a 401(k) plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports a routine transaction related to tax obligations. It doesn't inherently indicate positive or negative performance for the company.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders of a publicly traded company buy or sell the company's securities. This filing indicates a transaction by a key executive at Vertex Pharmaceuticals.
Stakeholder Impact
- The disposal of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the context of tax obligations.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of stock disposal transaction. |
| 02/19/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.